TaiGen Biotechnology

43 articles about TaiGen Biotechnology

• TaiGen Successfully Completes TG-1000 Phase III Study

  4/18/2024

  TaiGen Biotechnology Company, Limited announces that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study.

• TaiGen Enters Exclusive License Agreement with YSP

  10/11/2023

  TaiGen Biopharmaceuticals Holdings Ltd. announces that TaiGen Biotechnology, a subsidiary company of TaiGen, have signed an exclusive licensing agreement with Y.S.P. Industries Sdn. Bhd. to develop and commercialize TaiGen's new drug in Malaysia and Singapore.

• TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China

  3/22/2023

  TaiGen Biotechnology Company, Limited announces that they have signed an exclusive licensing agreement with Joincare Pharmaceutical Group Industry Co., Ltd., a top 10 China pharmaceutical company, to develop and commercialize TG-1000 in China.

• TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R)

  11/9/2020

  TaiGen Biotechnology Company, Limited announced that they have signed an exclusive agreement with GPCR Therapeutics, Inc., a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® in South Korea.

• TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000

  11/1/2020

  TaiGen Biotechnology Company, Limited announced that U.S. Food and Drug Administration has approved the Investigation New Drug application for TG-1000, a novel treatment for influenza A and B.

• TaiGen filed US IND for its influenza antiviral TG-1000

  10/4/2020

  TaiGen Biotechnology Company, Limited announced that it has filed an Investigational New Drug application with the US FDA for its influenza antiviral TG-1000.

• TaiGen Biotechnology Out-Licensed Taigexyn (Nemonoxacin) to Luminarie Canada for Canada, Australia and New Zealand

  9/30/2020

  TaiGen Biotechnology Company, Limited announced that they have signed an exclusive licensing agreement with Luminarie Canada Inc., a leading Canadian pharmaceutical company, to develop and commercialize Taigexyn® in Canada, Australia and New Zealand.

• HEC TaiGen Initiates Phase III Trial of Combination of Furaprevir and Yimitasvir for the Treatment of Chronic Hepatitis C Patients in China

  4/23/2019

  TaiGen Biotechnology Company, Limited announced that Phase III trial of the combination therapy Furaprevir - Yimitasvir for the treatment of chronic hepatitis C patients has been initiated.

• TaiGen Biotechnology Submits NDA In China For Novel IV Antibiotic

  5/31/2017

• TaiGen Biotechnology Announces Submission Of New Drug Application For Taigexyn Intravenous Formulation To The China Food And Drug Administration

  5/30/2017

• TaiGen Biotechnology And HEC Pharmaceutical Executed Equity Purchase Agreement For Their HCV Joint Venture

  3/27/2017

• TaiGen Biotechnology To Establish A New Company With HEC Pharmaceutical In China For Treatment Of Chronic Hepatitis C

  10/31/2016

• TaiGen Biotechnology Out-Licenses Taigexyn (Nemonoxacin) To Productos Científicos For The Latin American Market

  8/25/2016

• TaiGen Biotechnology Receives Market Approval From The China Food And Drug Administration For Taigexyn (Nemonoxacin)

  6/14/2016

• TaiGen Biotechnology Launches Taigexyn In Taiwan

  12/16/2015

• TaiGen Biotechnology's Intravenous Taigexyn Successfully Achieved Primary Endpoint In Phase 3 Clinical Trial For Community Acquired Pneumonia

  12/3/2015

• TaiGen Biotechnology Starts China Trial Of Novel Chemotherapy Sensitizer

  5/1/2015

• TaiGen Biotechnology Announces Initiation of Burixafor Chemosensitization Clinical Trial In Acute Myeloid Leukemia In China

  4/30/2015

• TaiGen Biotechnology Announces Burixafor Collaboration With Celldex And The University Hospital Carl Gustav Carus Dresden In Germany

  3/18/2015

• ScinoPharm To Provide Active Pharmaceutical Ingredient To TaiGen Biotechnology For Novel Stem Cell Drug

  6/9/2014